Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Why ENGlobal Corp. (ENG) Warrants a Second Glance as Small-Cap Investment Option

Houston-based ENGlobal (NASDAQ:ENG) is a specialty engineering firm charting its path to become a preferred provider of innovative automation integration services and select EPCM (engineering, procurement and construction management) projects worldwide. The company is specifically focused on oil and gas automation solutions, subsea control systems and engineering construction projects for energy and government sectors both domestically and abroad.

Through nearly 30 years of operations as a growing provider of energy-related automation and engineering services, ENGlobal has established several strategic business segments: Automation, EPCM, and Subsea Controls and Integration (SCI).

In addition to providing a range of services pertaining to the design, fabrication and implementation of distributed control, instrumentation and process analytical systems, ENGlobal’s Automation segment offers products and services supporting the environmental technology fields.

The EPCM segment provides consulting services for the development, management and execution of projects requiring professional engineering, construction management, and related support services. Within this segment, ENGlobal’s Government Services group provides engineering, design, installation and operation and maintenance of various government, public sector and international facilities, and specializes in the turnkey installation and maintenance of automation and instrumentation systems for the U.S. defense industry worldwide.

ENGlobal’s Subsea Controls and Integration (SCI) group provides advanced process automation design, engineering service and equipment for the effective integration of communication protocols between topsides production facilities and subsea devices. The SCI team was initiated when a major global E&P company set out to standardize the subsea process control environment. In 2008, ENGlobal’s SCI group was commissioned to further develop the concept commencing with a detailed design. Working together, they defined a long-term vision and commercialization plan for a now patented Universal Master Control Station (UMCS) that could communicate to virtually any subsea equipment.

As a top-ranked energy-related automation and engineering services provider, an effective and reliable workforce is key to successful operations. ENGlobal has created a global workforce of more than 400 industry leaders specialized and highly capable in all applicable fields. The company is guided by a highly experienced core leadership team that keeps the company on pace in a large and competitive market that includes Houston-based KBR, Inc. (NYSE: KBR), which serves the global hydrocarbons and government services industries; and California-based Jacobs Engineering Group, Inc. (NYSE:JEC).

While all three companies share similar offerings, ENGlobal’s smaller market cap and lower trading price makes it an attractive option for investors looking for a cheaper, but long-standing and reputable investment in the engineering space.

When you’re looking at ENGlobal as a potential investment, pair your own due diligence with the following highlights:

• Years of automation expertise and broad industry experience to customers worldwide
• Innovative, cost-effective automation, instrumentation and specialty construction projects
• Consistently ranked by Engineering News Record magazine as a Top 500 engineering design firm
• Complete range of fully integrated process, power and control solutions for projects worldwide
• Patented Universal Master Control Station™ (UMCS™) and industrial Heating, Ventilation and Air Conditioning HVAC™ solutions

For more information, visit www.englobal.com

Posted in ENGlobal Corp. ENG | Leave a comment

Digital Power Corp. (DPW) Addressing Demanding Market Applications with High-Grade Power System Solutions

Digital Power designs, develops, manufactures and sells high-grade customized and off-the-shelf power system solutions for the most demanding applications in the medical, military, telecom and industrial markets. In July, the company unveiled its newest family of products, which features a series of advanced, high-efficiency capacitor chargers specially designed for powering laser systems in medical and industrial applications. Through this release, DPW demonstrated its ongoing commitment to innovation in the development of best-in-class power solutions for a broad range of industries and challenging environments.

In recent months, DPW has built on this progress through efforts to further develop its product line offerings and geographical sales coverage. Despite recording a slight year-over-year decrease in revenues during the second quarter of 2015, increases in profitable defense-related shipments from its European operations throughout the first half of the year and continued expansion of its sales and marketing efforts could foreshadow an opportunity for the company to achieve considerable financial growth in the months to come.

“We continue to pursue our strategic plan of developing complete customized power solutions and enhancing our standard product portfolio with innovative, high density and efficient power supplies at ever increasing power levels,” Amos Kohn, president and chief executive officer of DPW, stated in a news release. “The focus on a complete solution for power applications is well received by our major telecom, medical, military and industrial customers.”

In June, the company provided prospective shareholders with a glimpse of the immense market potential of its product portfolio when it announced the execution of a 12-month, $1.2 million agreement to supply an industry-leading medical OEM with a universal power source solution for use in its portable oxygen concentrators. The customer selected DPW as a result of the company’s proven record of providing high quality, reliable power solutions to the medical industry. Moving forward, this agreement is expected to further strengthen DPW’s established position within the medical OEM marketplace.

Since being founded in 1969, DPW has grown into one of the most recognizable brands in the diversified electronics industry. With a healthy cash balance, an experienced management team and a portfolio of cutting-edge power system solutions, the company is in a strong strategic position to build upon this industry presence.

For more information, visit www.digipwr.com

Posted in Small Cap News | Leave a comment

International Stem Cell Corp. (ISCO) CSO to Present at Upcoming Rodman and Renshaw

International Stem Cell (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, this morning announced that company board member and Chief Scientific Officer Ruslan Semechkin, PhD, will present at the upcoming Rodman and Renshaw 17th Annual Global Investment Conference in New York.

Dr. Semechkin will provide a company overview and update on development of clinical and research programs when he takes the floor Wednesday, September 9, 2015, at 3 p.m. ET.

The company advises that you contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell’s management team.

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™.

International Stem Cell also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).

For more information visit www.internationalstemcell.com

Posted in International Stem Cell Corp. ISCO | Leave a comment

EquityFeed Hailed as the Most Actionable Stock Discovery Platform Ever Built

How do you find and profit from the best stock trading opportunities each day? If your daily routine includes checking your stocks and scouring the web for high quality plays, then you’re not alone. In the past, locating the best investment opportunities was a timely, inefficient process, but those days are over thanks to EquityFeed.

EquityFeed is a real-time, actionable information platform specially designed to suit the needs of individual stock traders – including those of you trading from home. The platform’s ultra-powerful scanning functionality is ideal for traders who don’t mind gaining an unfair advantage in their stock hunting efforts. Seriously, it’s like shooting fish in a barrel!

Start by creating customized and incredibly powerful filters for your specific intraday trading routine. With these filters in place, the stocks you want to know about will come to you instead of you looking for them. The EquityFeed filter builder provides the options needed to fully personalize your experience while promoting optimal results.

One of the most exciting features of the EquityFeed platform is its complete alert management interface. If a stock that may be in your wheelhouse demonstrates patterns and technical events worthy of your attention, EquityFeed will let you know. In other words, you’ll be ready to capitalize on stocks that are making new highs, new lows, breaking price averages, breaking volume averages, moving large block trades and much more without the need to spend your valuable time searching for easy-to-miss action.

Once you’ve got a stock in your sights, EquityFeed’s proprietary decision support mechanic is the perfect tool for helping you pull the trigger with confidence. The chart montage is your go-to source for more in-depth information after an interesting stock has been identified. Featuring a clean and compact design, this window will deliver all the real-time data needed to help ensure that the stock on your mind is a worthwhile investment.

If, for some reason, you’re not ready to move on a particular stock, you’ll be able to keep it within reach through the use of EquityFeed’s intuitive limit alerts feature. Just add the stock, and you’ll be alerted when news is released or a specified threshold, such as price, volume, bid, ask or change, is crossed. With EquityFeed, you’ll be able to go on with your business without taking your finger off the pulse of the market.

All of these features, along with the option to seamlessly integrate with many of the country’s most popular brokers for instant trade execution and unrivalled speed, combine to make EquityFeed a truly revolutionary approach to the stock discovery platform. If you’re ready to make your daily routine more efficient while simultaneously promoting bigger earnings, you’ll want to check out the free 14-day trial.

For more information, visit www.dtn.fm/equityfeed-trial

Posted in Small Cap News | Leave a comment

Erin Energy Corp. (ERN) Building Shareholder Value through Exploration and Development of Assets in Sub-Saharan Africa

Erin Energy is an independent oil and gas exploration and production company focused on energy resources in sub-Saharan Africa. The company’s asset portfolio includes nine licenses across four countries covering an area of approximately 16,600 square miles, including current production and exploration projects offshore Nigeria, as well as exploration licenses offshore Ghana and the Gambia and both offshore and onshore Kenya. By expertly managing its investments and on-going operations, Erin Energy is able to combat current market conditions by limiting capital exposure while maintaining economic efficiency in its operations and maximizing investment value.

In recent months, the company has made tremendous progress in advancing its exploration and development programs. On its project in Nigeria, Erin Energy successfully tied in two wells, Oyo-7 and Oyo-8, in the Oyo field. This achievement preceded the commencement of production in May. In total, the two wells accounted for production of more than 450,000 barrels of oil in the second quarter of 2015, giving the company considerable momentum as it looks to increase its production capacity moving forward.

“Bringing the Oyo-7 and Oyo-8 wells on production were significant milestones in the company’s history,” Kase Lawal, chairman and chief executive officer of Erin Energy, stated in a news release. “Growth is at the center of Erin Energy and this achievement is just the beginning for us.”

The company’s recent progress in the development of its Nigeria asset has been accompanied by equally noteworthy progress on other assets in its portfolio. On August 21, Erin Energy announced that it had received approval from the government of Kenya to enter the first additional exploration period on its onshore blocks, L1B and L16. According to the terms of this approval, the company will be required to acquire, process and interpret approximately 116 square miles of 3D seismic data and drill one exploration well on each block within the next two years.

“We are very pleased to begin the next phase of exploration in Kenya,” continued Lawal. “Our team is greatly encouraged by the results of our exploration efforts thus far, and excited by the significant hydrocarbon potential we see on the blocks.”

Since the start of oil production, the company’s wells have consistently outperformed pre-drill projections. As of August 1, the combined production rate of Oyo-7 and Oyo-8 was approximately 13,100 barrels of oil per day, giving Erin Energy a strong channel with which to generate revenue while continuing to expand its operations. Look for the company to build on these strong results as it progresses exploration efforts across its sizable asset portfolio in the months to come.

For more information, visit www.erinenergy.com

Posted in Small Cap News | Leave a comment

Skyline Medical, Inc. (SKLN) (SKLNU) Providing a Safer Approach to Surgical Waste Handling with Innovative STREAMWAY® System

Skyline Medical, Inc. (NASDAQ: SKLN, SKLNU) is a medical device company engaged in the production and commercialization of an innovative, environmentally-friendly tool targeted at improving the safety of one of the most dangerous jobs in the medical field. The company’s proprietary STREAMWAY® system is a cost-effective, canister-free platform that eliminates the frequent and potentially hazardous interruptions commonly associated with surgical waste handling. Utilizing a direct-to-drain installation, Skyline’s technology greatly reduces the risk of hospital staff being exposed to biohazard fluids while simultaneously promoting improved patient-focused care and significant time savings.

The immense benefits of the STREAMWAY system have helped the company make considerable strides toward achieving sustainable market growth in recent years. Originally released in 2009, Skyline has sold 89 units to date, and the company expects this figure to rapidly expand as it looks to bolster sales and production efforts. As new hospitals continue to approve the use of the groundbreaking STREAMWAY system for additional applications, Skyline expects to significantly improve its financial results.

In the first quarter of 2015, Skyline successfully leveraged the marketability of its innovative system to promote strong financial growth. In addition to selling and shipping five STREAMWAY units, the company realized a 115 percent year-over-year increase in total revenues, recording $151,274 for the period. Likewise, Skyline’s net loss and total expenses were reduced by more than $1.3 million during the quarter, as compared to the previous year.

“Our sales increased year-over-year as we continue to make sales to large and diverse medical centers across a broader geographical area,” Josh Kornberg, chief executive officer of Skyline, stated in a news release. “We are optimistic about our business opportunities as we execute on our sales strategy.”

In recent weeks, Skyline has turned its attention toward increasing its market visibility and securing the capital necessary to continue progressing with its strategic business plan. The company recently announced a public offering that’s expected to raise approximately $15 million to fund its ongoing sales efforts while allowing Skyline to increase its product inventory in the future. These actions will be a key part of Skyline’s progress toward market growth, particularly as the company targets achieving profitability as early as next year.

For prospective shareholders, the increasingly widespread adoption of Skyline’s proprietary STREAMWAY technology could provide a platform for ongoing growth. Look for the company to benefit from an improved cash position following the completion of its upcoming public offering as it continues to build upon it recent progress in the future.

For more information, visit www.skylinemedical.com

Posted in Small Cap News | Leave a comment

Catalyst Pharmaceuticals, Inc. (CPRX) Rapidly Approaching Commercialization of Firdapse®

Catalyst Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies for people with rare debilitating diseases. The company’s lead product candidate, Firdapse®, recently completed a pivotal phase III clinical trial for the treatment of Lambert-Eaton myasthenic symdrome (LEMS), a rare neuromuscular, autoimmune disorder that afflicts about 3,000 people in the United States. Catalyst took a significant step toward the eventual commercialization of its innovative candidate when it initiated submission of a rolling new drug application (NDA) to the U.S. Food and Drug Administration (FDA) earlier this year. The company anticipates completing this submission during the fourth quarter, putting it on schedule for approval in the first half of 2016.

“[W]e have been working diligently to advance regulatory and commercial affairs and are pleased with the initiation of our rolling NDA submission to the FDA for Firdapse,” Patrick J. McEnany, chief executive officer of Catalyst, stated in a news release. “Additionally, we are on schedule with our key commercial strategic imperatives to support the successful launch of Firdapse.”

Catalyst’s development pipeline also includes CPP-115, which is being studied for the treatment of infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette’s disease. CPP-115 has been granted U.S. orphan drug designation by the FDA for the treatment of infantile spasms, making it eligible for a host of incentives designed to limit the costs associated with future development efforts.

In February, the company completed an offering of common stock that raised net proceeds of approximately $34.9 million to help fund its promising development programs. As of June 30, Catalyst reported cash and cash equivalents of $67.4 million with no outstanding debt. These considerable resources are expected to fund the company’s ongoing operations through the anticipated approval and subsequent product launch of Firdapse in 2016.

As it approaches the commercial launch of Firdapse, Catalyst is in a favorable position to promote strong financial growth. Look for the company to benefit from the operational flexibility afforded by its strong balance sheet as it focuses on making significant progress with the ongoing development of its product pipeline.

For more information, visit www.catalystpharma.com

Posted in Small Cap News | Leave a comment

International Stem Cell Corp. (ISCO): A Double Threat with Cutting-Edge, Ethically Derived Stem Cell Therapies & Commercial-Scale Biobanking

On the cusp of milestone TGA (Therapeutic Goods Administration) authorization in Australia to start clinical trials in its breakthrough Parkinson’s disease (PD) treatment using human parthenogenetic neural stem cells (hpNSCs), International Stem Cell Corp. (OTCQB: ISCO) was proud to show markets recently that the company has achieved a point of maturity where it is also driving home steadily increasing revenues. The release of the company’s Q2 2015 data also showed record net income for the quarter, with outlays decreasing due to having successfully wrapped on a number of important preclinical studies, even as revenues increased 14 percent year over year, and profit margins held steady at around 72 percent.

The company’s increasingly lucrative biomedical business and consistently profitable regenerative skin care offerings, administrated respectively via ISCO’s wholly-owned Lifeline Cell Technology and Lifeline Skin Care subsidiaries, continue to materially backstop the ongoing development of an exciting therapeutic pipeline based on proprietary human parthenogenetic stem cell (hpSC) technology which is efficient, perfect for commercial scale volumes, and also completely ethical. ISCO’s parthenogenesis technology employs a unique chemical stimulation technique for triggering unfertilized donor human eggs to create pluripotent cells that can then be differentiated through proprietary activation into numerous types of cells. From the aforementioned hpNSCs, which are increasingly seen via the company’s trial work as a paradigm shift approach when it comes to treating neurological system conditions like PD and even ischemic stroke. To liver and eye cells that can be used to effectively treat degenerative diseases affecting those tissue systems, such as metabolic liver disease and macular degeneration.

Just looking at the company’s application of hpNSCs in PD, we see a fundamentally new approach to therapy using transplanted stem cells, which could actually solve the underlying problems that give rise to such conditions, rather than just attempting to ameliorate the condition as with many other therapies, including the current standards of care. In PD, where injected hpNSCs actively differentiate into both dopaminergic neurons, as well as express brain-protecting neurotrophic factors, and thus directly address the two primary causes of debilitation, this approach shows its monumental superiority to other approaches by simultaneously replacing dead neurons and protecting any survivors. This kind of therapeutic solution constitutes an end-run on PD, and potentially many other diseases/disorders via a completely ethical, high-volume stem cell production technology, and it could make ISCO into one of the now $27 billion plus global stem cell market’s heaviest hitters.

Recent projections by Transparency Market Research indicate that the global stem cell market is just getting warmed up too. With around 24 percent CAGR seen occurring through 2018 and valuations the following year of as much as $119 billion or more, this highly fragmented market is primed for explosive growth. Something which is especially true for real innovators like ISCO, given that pluripotent stem cells are also seen as rapidly eclipsing the core adult stem cell type that currently has around 80 percent of the market share.

Perhaps even more importantly, the company’s UniStemCell bank, which is effectively the life science industry’s first commercial-scale aggregation of histocompatible, non-embryonic human stem cells, is ideally positioned to benefit from the continued upswing in the sector. Providing a growing logistical footprint of high-quality material for research purposes, as well as commercial applications. Moreover, ISCO has established a solid presence already here in the U.S., which is the epicenter of global activity for the stem cell industry due to federal government support for the sector. As the biobanking market expands further into Europe and other global markets, the company will benefit from first-mover advantages.

To take a closer look, visit www.internationalstemcell.com

Posted in International Stem Cell Corp. ISCO | Leave a comment

ENGlobal Corp. (ENG) Expands Management Team

ENGlobal, a leading provider of automation and engineering services, announced this morning that it has added two key professionals to its management team in newly created positions. The decision to expand its leadership team was made to support the company’s strategic commitment to further strengthen its midstream project execution and automation engineering businesses.

John Offutt will be serving as General Manager — Midstream Projects, with responsibility of the company’s Tulsa and Houston midstream operations.  Offutt brings his knowledge and experience in managing all phases of large transportation-related projects, with the majority of his 30-year career having been with a major midstream operating company.

In his most recent assignment, Offutt managed a $700 million capital budget including 280 miles of pipeline and associated facilities. Offutt has directed teams of project managers, engineers, construction managers and support functions, being responsible for the successful execution of a lengthy list of both large and small diameter pipeline projects.

Robert Sammons will be serving as general manager — Automation Engineering. In his role, Sammons will be expanding ENGlobal’s automation capabilities, in addition to supervising several of the company’s existing projects and technologies.

Sammons has gained extensive automation experience during his 25 year career, with senior level responsibilities focused on both business development and operations. Most recently he has been active in his own business providing Process Hazard Analysis and Burner Management Safety systems to midstream processing, refining and petrochemical clients.

“ENGlobal is privileged to include both John and Robert as senior professionals and members of the ENGlobal Team,” William A. Coskey, P.E., ENGlobal’s chairman and chief executive officer, stated in the news release.  “Our intent in the current market is to remain dynamic and proactive as a company, building upon our many project execution skills and thereby demonstrating our continuous commitment to better serve our valued clients.”

For more information, visit www.ENGlobal.com

Posted in ENGlobal Corp. ENG | Leave a comment

ENGlobal Corporation (ENG) Leaning on Experience of Leadership Team to Promote Profitability Despite Slumping Energy Prices

In recent weeks, ENGlobal Corporation (NASDAQ: ENG) has provided prospective shareholders with a glimpse into its considerable growth potential. Despite slumping energy prices, the company demonstrated its versatility in the second quarter of 2015 by recording its sixth straight quarter of profitability. This accomplishment is validation of ENGlobal’s recent efforts to streamline its operations while continuing to promote market growth. In particular, the company has maintained strict levels of control over overhead costs in its two operating segments – engineering, procurement and construction management (EPCM) and automation – while continuing to closely monitor the spending of its clients.

“ENGlobal’s profit margins remain respectable given the current environment, and our available capital has improved over the last year,” Mark Hess, chief financial officer of ENGlobal, stated in a news release earlier this month. “The Company continues to maintain a healthy cash balance and working capital of $25.4 million, and we have no borrowings under our current credit facility.”

In the company’s quarterly report, it highlighted the high level of proposal activity it’s seen in recent months, which could provide an indication as to its market potential moving forward. By minimizing costs, ENGlobal has ensured that its services have remained very competitive while it continues to focus on marketing centered on its differentiated products and services. Additionally, the company has been vocal about the possibility of capitalizing on current energy market conditions by purchasing proprietary or differentiated technologies or processes in order to increase the marketability of its unique portfolio in the future.

“ENGlobal’s response to the current energy marketplace has been to increase our efforts in developing new business,” William Coskey, P.E., chairman and chief executive officer of ENGlobal, stated. “While we are excited about several new opportunities and client relationships that this internal process has produced, it also appears to be a great time to consider strategic acquisitions.”

With a strong balance sheet in place, ENGlobal will lean on the immense industry experience of its management team as it looks to adapt to current market conditions. In total, the company’s leadership team brings well over a century of combined experience to the table. William Coskey, the company’s president and CEO, has served in his current position since 2012, and he has been with ENGlobal in some capacity since its founding in 1985. This management stability should provide the company with an advantage as it looks to navigate the current energy market.

The company’s ability to remain profitable despite slumping oil and gas prices is a positive indication of its potential in the months to come. Look for ENGlobal to continue limiting unnecessary costs while leveraging the flexibility provided by its strong cash balance in order to explore strategic acquisition opportunities in the months to come.

For more information, visit www.englobal.com

Posted in ENGlobal Corp. ENG | Leave a comment